ROBERT LOEHR: Open Payments
NPI 1851351464 · LAWRENCE, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,464 in 78 payments from 10 companies in 2025. Trend: 2023 $237 · 2024 $910 · 2025 $1,464
Food & beverage: $1,458Education: $7
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 10 | $348 |
| ABBVIE INC. | 19 | $289 |
| Teva Pharmaceuticals USA, Inc. | 16 | $245 |
| Vanda Pharmaceuticals Inc. | 16 | $242 |
| Alkermes, Inc. | 10 | $200 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Janssen Pharmaceuticals, Inc | 1 | $14 |
| Corium, LLC | 1 | $13 |
Products named: COBENFY, VRAYLAR, AUSTEDO XR, HETLIOZ, ARISTADA, REXULTI, LYBALVI, FANAPT.
Industry payments across KS — which companies pay providers there.
